img

Global Targeted Therapy for Bladder Cancer Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Targeted Therapy for Bladder Cancer Market Insights, Forecast to 2034

Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
Market Analysis and InsightsGlobal Targeted Therapy for Bladder Cancer Market
Global Targeted Therapy for Bladder Cancer market is expected to reach to US$ 834 million in 2024, with a positive growth of %, compared with US$ 758 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Targeted Therapy for Bladder Cancer industry is evaluated to reach US$ 1414.2 million in 2029. The CAGR will be 9.2% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Targeted Therapy for Bladder Cancer market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Targeted Therapy for Bladder Cancer market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Segment by Type
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other

Segment by Application


Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Targeted Therapy for Bladder Cancer introduction, etc. Targeted Therapy for Bladder Cancer Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Targeted Therapy for Bladder Cancer
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Therapy for Bladder Cancer Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Atezolizumab (Tecentriq)
1.2.3 Avelumab (Bavencio)
1.2.4 Erdafitinib (Balversa)
1.2.5 Other
1.3 Market by Application
1.3.1 Global Targeted Therapy for Bladder Cancer Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Therapy for Bladder Cancer Market Perspective (2018-2029)
2.2 Global Targeted Therapy for Bladder Cancer Growth Trends by Region
2.2.1 Targeted Therapy for Bladder Cancer Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Targeted Therapy for Bladder Cancer Historic Market Size by Region (2018-2024)
2.2.3 Targeted Therapy for Bladder Cancer Forecasted Market Size by Region (2024-2029)
2.3 Targeted Therapy for Bladder Cancer Market Dynamics
2.3.1 Targeted Therapy for Bladder Cancer Industry Trends
2.3.2 Targeted Therapy for Bladder Cancer Market Drivers
2.3.3 Targeted Therapy for Bladder Cancer Market Challenges
2.3.4 Targeted Therapy for Bladder Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Targeted Therapy for Bladder Cancer by Players
3.1.1 Global Targeted Therapy for Bladder Cancer Revenue by Players (2018-2024)
3.1.2 Global Targeted Therapy for Bladder Cancer Revenue Market Share by Players (2018-2024)
3.2 Global Targeted Therapy for Bladder Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Targeted Therapy for Bladder Cancer, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Targeted Therapy for Bladder Cancer Market Concentration Ratio
3.4.1 Global Targeted Therapy for Bladder Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Therapy for Bladder Cancer Revenue in 2022
3.5 Global Key Players of Targeted Therapy for Bladder Cancer Head office and Area Served
3.6 Global Key Players of Targeted Therapy for Bladder Cancer, Product and Application
3.7 Global Key Players of Targeted Therapy for Bladder Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Therapy for Bladder Cancer Breakdown Data by Type
4.1 Global Targeted Therapy for Bladder Cancer Historic Market Size by Type (2018-2024)
4.2 Global Targeted Therapy for Bladder Cancer Forecasted Market Size by Type (2024-2029)
5 Targeted Therapy for Bladder Cancer Breakdown Data by Application
5.1 Global Targeted Therapy for Bladder Cancer Historic Market Size by Application (2018-2024)
5.2 Global Targeted Therapy for Bladder Cancer Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Targeted Therapy for Bladder Cancer Market Size (2018-2029)
6.2 North America Targeted Therapy for Bladder Cancer Market Size by Type
6.2.1 North America Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024)
6.2.2 North America Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029)
6.2.3 North America Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
6.3 North America Targeted Therapy for Bladder Cancer Market Size by Application
6.3.1 North America Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024)
6.3.2 North America Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029)
6.3.3 North America Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
6.4 North America Targeted Therapy for Bladder Cancer Market Size by Country
6.4.1 North America Targeted Therapy for Bladder Cancer Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Targeted Therapy for Bladder Cancer Market Size by Country (2018-2024)
6.4.3 North America Targeted Therapy for Bladder Cancer Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Targeted Therapy for Bladder Cancer Market Size (2018-2029)
7.2 Europe Targeted Therapy for Bladder Cancer Market Size by Type
7.2.1 Europe Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024)
7.2.2 Europe Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029)
7.2.3 Europe Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
7.3 Europe Targeted Therapy for Bladder Cancer Market Size by Application
7.3.1 Europe Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024)
7.3.2 Europe Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029)
7.3.3 Europe Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
7.4 Europe Targeted Therapy for Bladder Cancer Market Size by Country
7.4.1 Europe Targeted Therapy for Bladder Cancer Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Targeted Therapy for Bladder Cancer Market Size by Country (2018-2024)
7.4.3 Europe Targeted Therapy for Bladder Cancer Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Targeted Therapy for Bladder Cancer Market Size (2018-2029)
8.2 China Targeted Therapy for Bladder Cancer Market Size by Type
8.2.1 China Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024)
8.2.2 China Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029)
8.2.3 China Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
8.3 China Targeted Therapy for Bladder Cancer Market Size by Application
8.3.1 China Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024)
8.3.2 China Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029)
8.3.3 China Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Targeted Therapy for Bladder Cancer Market Size (2018-2029)
9.2 Asia Targeted Therapy for Bladder Cancer Market Size by Type
9.2.1 Asia Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024)
9.2.2 Asia Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029)
9.2.3 Asia Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
9.3 Asia Targeted Therapy for Bladder Cancer Market Size by Application
9.3.1 Asia Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024)
9.3.2 Asia Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029)
9.3.3 Asia Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
9.4 Asia Targeted Therapy for Bladder Cancer Market Size by Region
9.4.1 Asia Targeted Therapy for Bladder Cancer Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Targeted Therapy for Bladder Cancer Market Size by Region (2018-2024)
9.4.3 Asia Targeted Therapy for Bladder Cancer Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Type
10.2.1 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Application
10.3.1 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Country
10.4.1 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Targeted Therapy for Bladder Cancer Introduction
11.1.4 Pfizer Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.1.5 Pfizer Recent Developments
11.2 Merck KGaA
11.2.1 Merck KGaA Company Details
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Targeted Therapy for Bladder Cancer Introduction
11.2.4 Merck KGaA Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.2.5 Merck KGaA Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Targeted Therapy for Bladder Cancer Introduction
11.3.4 Roche Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.3.5 Roche Recent Developments
11.4 Astellas
11.4.1 Astellas Company Details
11.4.2 Astellas Business Overview
11.4.3 Astellas Targeted Therapy for Bladder Cancer Introduction
11.4.4 Astellas Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.4.5 Astellas Recent Developments
11.5 Janssen Biotech
11.5.1 Janssen Biotech Company Details
11.5.2 Janssen Biotech Business Overview
11.5.3 Janssen Biotech Targeted Therapy for Bladder Cancer Introduction
11.5.4 Janssen Biotech Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.5.5 Janssen Biotech Recent Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Introduction
11.6.4 Bristol-Myers Squibb Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.6.5 Bristol-Myers Squibb Recent Developments
11.7 Merck & Co.
11.7.1 Merck & Co. Company Details
11.7.2 Merck & Co. Business Overview
11.7.3 Merck & Co. Targeted Therapy for Bladder Cancer Introduction
11.7.4 Merck & Co. Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.7.5 Merck & Co. Recent Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Targeted Therapy for Bladder Cancer Introduction
11.8.4 Gilead Sciences Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024)
11.8.5 Gilead Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Targeted Therapy for Bladder Cancer Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Atezolizumab (Tecentriq)
Table 3. Key Players of Avelumab (Bavencio)
Table 4. Key Players of Erdafitinib (Balversa)
Table 5. Key Players of Other
Table 6. Global Targeted Therapy for Bladder Cancer Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Targeted Therapy for Bladder Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Targeted Therapy for Bladder Cancer Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Targeted Therapy for Bladder Cancer Market Share by Region (2018-2024)
Table 10. Global Targeted Therapy for Bladder Cancer Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Targeted Therapy for Bladder Cancer Market Share by Region (2024-2029)
Table 12. Targeted Therapy for Bladder Cancer Market Trends
Table 13. Targeted Therapy for Bladder Cancer Market Drivers
Table 14. Targeted Therapy for Bladder Cancer Market Challenges
Table 15. Targeted Therapy for Bladder Cancer Market Restraints
Table 16. Global Targeted Therapy for Bladder Cancer Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Targeted Therapy for Bladder Cancer Revenue Share by Players (2018-2024)
Table 18. Global Top Targeted Therapy for Bladder Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Therapy for Bladder Cancer as of 2022)
Table 19. Global Targeted Therapy for Bladder Cancer Industry Ranking 2021 VS 2022 VS 2024
Table 20. Global 5 Largest Players Market Share by Targeted Therapy for Bladder Cancer Revenue (CR5 and HHI) & (2018-2024)
Table 21. Global Key Players of Targeted Therapy for Bladder Cancer, Headquarters and Area Served
Table 22. Global Key Players of Targeted Therapy for Bladder Cancer, Product and Application
Table 23. Global Key Players of Targeted Therapy for Bladder Cancer, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Targeted Therapy for Bladder Cancer Revenue Market Share by Type (2018-2024)
Table 27. Global Targeted Therapy for Bladder Cancer Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Targeted Therapy for Bladder Cancer Revenue Market Share by Type (2024-2029)
Table 29. Global Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Targeted Therapy for Bladder Cancer Revenue Share by Application (2018-2024)
Table 31. Global Targeted Therapy for Bladder Cancer Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Targeted Therapy for Bladder Cancer Revenue Share by Application (2024-2029)
Table 33. North America Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024) & (US$ Million)
Table 34. North America Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024) & (US$ Million)
Table 36. North America Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Targeted Therapy for Bladder Cancer Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Targeted Therapy for Bladder Cancer Market Size by Country (2018-2024) & (US$ Million)
Table 39. North America Targeted Therapy for Bladder Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024) & (US$ Million)
Table 41. Europe Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024) & (US$ Million)
Table 43. Europe Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Targeted Therapy for Bladder Cancer Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Targeted Therapy for Bladder Cancer Market Size by Country (2018-2024) & (US$ Million)
Table 46. Europe Targeted Therapy for Bladder Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024) & (US$ Million)
Table 48. China Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024) & (US$ Million)
Table 50. China Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024) & (US$ Million)
Table 52. Asia Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024) & (US$ Million)
Table 54. Asia Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Targeted Therapy for Bladder Cancer Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Targeted Therapy for Bladder Cancer Market Size by Region (2018-2024) & (US$ Million)
Table 57. Asia Targeted Therapy for Bladder Cancer Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Type (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Application (2018-2024) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Country (2018-2024) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 65. Pfizer Company Details
Table 66. Pfizer Business Overview
Table 67. Pfizer Targeted Therapy for Bladder Cancer Product
Table 68. Pfizer Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 69. Pfizer Recent Developments
Table 70. Merck KGaA Company Details
Table 71. Merck KGaA Business Overview
Table 72. Merck KGaA Targeted Therapy for Bladder Cancer Product
Table 73. Merck KGaA Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 74. Merck KGaA Recent Developments
Table 75. Roche Company Details
Table 76. Roche Business Overview
Table 77. Roche Targeted Therapy for Bladder Cancer Product
Table 78. Roche Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 79. Roche Recent Developments
Table 80. Astellas Company Details
Table 81. Astellas Business Overview
Table 82. Astellas Targeted Therapy for Bladder Cancer Product
Table 83. Astellas Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 84. Astellas Recent Developments
Table 85. Janssen Biotech Company Details
Table 86. Janssen Biotech Business Overview
Table 87. Janssen Biotech Targeted Therapy for Bladder Cancer Product
Table 88. Janssen Biotech Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 89. Janssen Biotech Recent Developments
Table 90. Bristol-Myers Squibb Company Details
Table 91. Bristol-Myers Squibb Business Overview
Table 92. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Product
Table 93. Bristol-Myers Squibb Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 94. Bristol-Myers Squibb Recent Developments
Table 95. Merck & Co. Company Details
Table 96. Merck & Co. Business Overview
Table 97. Merck & Co. Targeted Therapy for Bladder Cancer Product
Table 98. Merck & Co. Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 99. Merck & Co. Recent Developments
Table 100. Gilead Sciences Company Details
Table 101. Gilead Sciences Business Overview
Table 102. Gilead Sciences Targeted Therapy for Bladder Cancer Product
Table 103. Gilead Sciences Revenue in Targeted Therapy for Bladder Cancer Business (2018-2024) & (US$ Million)
Table 104. Gilead Sciences Recent Developments
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Targeted Therapy for Bladder Cancer Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Targeted Therapy for Bladder Cancer Market Share by Type: 2022 VS 2029
Figure 3. Atezolizumab (Tecentriq) Features
Figure 4. Avelumab (Bavencio) Features
Figure 5. Erdafitinib (Balversa) Features
Figure 6. Other Features
Figure 7. Global Targeted Therapy for Bladder Cancer Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Targeted Therapy for Bladder Cancer Market Share by Application: 2022 VS 2029
Figure 9. Hospital Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Other Case Studies
Figure 12. Targeted Therapy for Bladder Cancer Report Years Considered
Figure 13. Global Targeted Therapy for Bladder Cancer Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Targeted Therapy for Bladder Cancer Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Targeted Therapy for Bladder Cancer Market Share by Region: 2022 VS 2029
Figure 16. Global Targeted Therapy for Bladder Cancer Market Share by Players in 2022
Figure 17. Global Top Targeted Therapy for Bladder Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Therapy for Bladder Cancer as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Targeted Therapy for Bladder Cancer Revenue in 2022
Figure 19. North America Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
Figure 21. North America Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
Figure 22. North America Targeted Therapy for Bladder Cancer Market Share by Country (2018-2029)
Figure 23. United States Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Targeted Therapy for Bladder Cancer Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
Figure 27. Europe Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
Figure 28. Europe Targeted Therapy for Bladder Cancer Market Share by Country (2018-2029)
Figure 29. Germany Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Targeted Therapy for Bladder Cancer Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
Figure 37. China Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
Figure 38. Asia Targeted Therapy for Bladder Cancer Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
Figure 40. Asia Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
Figure 41. Asia Targeted Therapy for Bladder Cancer Market Share by Region (2018-2029)
Figure 42. Japan Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Targeted Therapy for Bladder Cancer Market Share by Country (2018-2029)
Figure 52. Brazil Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Targeted Therapy for Bladder Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Pfizer Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 59. Merck KGaA Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 60. Roche Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 61. Astellas Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 62. Janssen Biotech Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 64. Merck & Co. Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 65. Gilead Sciences Revenue Growth Rate in Targeted Therapy for Bladder Cancer Business (2018-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries